In at least one-quarter to one-third of HER2-positive breast cancers there are dysregulated, HER2-independent activation of the PI3K pathway by mutation of PIK3CA or loss of PTEN [10,11]. The gene discussed is ERBB2; the disease is breast carcinoma.